CurrentCignaPolicy N/A

Oncology - Bexarotene (Topical) Prior Authorization Policy

Defines prior authorization requirements and coverage criteria for topical bexarotene (Targretin® 1% gel) for prescription benefit plans administered by Cigna companies, applicable to prescribers and reviewers assessing medical necessity.

Policy Summary

PayerCigna

PolicyOncology - Bexarotene (Topical) Prior Authorization Policy

Policy CodePolicy N/A

Change TypeAdded other-use indications (Adult T‑Cell Leukemia/LymphomaPrimary Cutaneous B‑Cell Lymphoma) and refined subtype language

Effective DateN/A

Next Review DateDec 11, 2024

Key ActionObtain prior authorization and document specialist prescribing or consultation (oncologist or dermatologist); approvals granted for 1 year when criteria are met.

SourceLink

POLICY UPDATE CHANGES

Adult T-Cell Leukemia/Lymphoma indication added under 'Other Uses with Supportive Evidence.' with approval criteria.

For Adult T-Cell Leukemia/Lymphoma the 'chronic' subtype was removed and 'symptomatic' qualifier added for smoldering subtype in prior revision history.

Primary Cutaneous B-Cell Lymphoma added as an other-use indication with specific lymphoma subtypes listed.

1 yearApproval duration

Stage IA-IBFDA CTCL stages

2Other supportive uses

Specialist required

Policy Summary

PayerCigna

PolicyOncology - Bexarotene (Topical) Prior Authorization Policy

Policy CodePolicy N/A

Change TypeAdded other-use indications (Adult T‑Cell Leukemia/LymphomaPrimary Cutaneous B‑Cell Lymphoma) and refined subtype language

Effective DateN/A

Next Review DateDec 11, 2024

Key ActionObtain prior authorization and document specialist prescribing or consultation (oncologist or dermatologist); approvals granted for 1 year when criteria are met.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

inv-01: Initial: FDA-Approved Indication (CTCL)

Covered when ALL of the following are met for the FDA-approved indication:

FDA-Approved Indication: Cutaneous T-Cell Lymphoma: A) Patient has cutaneous manifestations/lesions; AND B) The medication is prescribed by or in consultation with an oncologist or a dermatologist.

Approve for 1 year if both conditions are met.

inv-02: Other Use: Adult T-Cell Leukemia/Lymphoma

Covered when ALL of the following are met for Adult T-Cell Leukemia/Lymphoma (other use with supportive evidence):

Adult T-Cell Leukemia/Lymphoma (smoldering symptomatic): A) Patient has smoldering symptomatic subtype; AND B) Medication is used as first-line therapy; AND C) The medication is prescribed by or in consultation with an oncologist or a dermatologist.

Approve for 1 year if all conditions are met.

inv-03: Other Use: Primary Cutaneous B-Cell Lymphoma

Covered when ALL of the following are met for Primary Cutaneous B-Cell Lymphoma (other use with supportive evidence):

Primary Cutaneous B-Cell Lymphoma: A) Medication is used as skin-directed therapy for ONE of: i) Primary cutaneous marginal zone lymphoma; OR ii) Follicle center lymphoma; AND B) The medication is prescribed by or in consultation with an oncologist or a dermatologist.

Approve for 1 year if both conditions are met.

Use of topical bexarotene (Targretin® 1% gel) for any indication not specifically listed in this policy is considered experimental, investigational, or unproven. Coverage for unlisted uses will not be authorized and the policy criteria will be updated if new published data supporting additional indications become available.

Provider Actions and Requirements

Prior Authorization

Prior Authorization Recommended

Prior authorization is recommended for bexarotene gel; when criteria are met approvals are granted for 1 year.

Approval duration: 1 year when medical criteria met
Prior authorization recommended for prescription benefit coverage

Documentation Required

Prescriber Specialty and Documentation

Because of the specialized skills required for evaluation, diagnosis, and monitoring of patients treated with bexarotene gel, the medication must be prescribed by or in consultation with a physician who specializes in the condition being treated.

Prescriber requirement: oncologist or dermatologist, or documented consultation with one

Line of Therapy

inv-12: first-line

Line of therapy for Adult T-Cell Leukemia/Lymphoma: Medication is used as first-line therapy for smoldering symptomatic subtype.

inv-13: first-line

CTCL therapy context: NCCN lists topical bexarotene as an option for initial therapy and for relapsed/refractory cases (category 2A).

Background

Topical bexarotene gel is approved for the treatment of cutaneous lesions in patients with cutaneous T‑cell lymphoma (Stage IA and IB). It is typically used as a skin‑directed therapy for lesions and may be considered in patients with refractory, persistent, or intolerant responses to other therapies; prescribing and prior‑authorization expectations follow the FDA indication and relevant guideline context.

Definitions

Definition — cutaneous T‑cell lymphoma

TermCutaneous T-Cell Lymphoma (CTCL)

FDA‑Indicated stagesStage IA and IB

Clinical contextTopical bexarotene gel is indicated for topical treatment of cutaneous lesions in patients with CTCL who have refractory or persistent disease after other therapies or who have not tolerated other therapies.

Approval duration when criteria metApprove for 1 year

Definition — smoldering symptomatic adult T‑cell leukemia/lymphoma

TermSmoldering symptomatic adult T‑cell leukemia/lymphoma

Line of therapy

Step Therapy

Therapy Context and Prior Treatments

Bexarotene gel is intended for use in patients with cutaneous manifestations who have refractory or persistent disease after other therapies or who have not tolerated other therapies (for CTCL). For other supported indications, therapy context expectations are specified (e.g., first-line skin-directed therapy for smoldering symptomatic adult T‑cell leukemia/lymphoma; skin-directed therapy for selected primary cutaneous B‑cell lymphomas). Documentation of prior therapies, intolerance, or rationale for first‑line use (when applicable) should be provided.

CTCL (FDA‑approved): refractory or persistent cutaneous disease after other therapies or intolerance to other therapies
Adult T‑cell leukemia/lymphoma: used as first‑line skin‑directed therapy for smoldering symptomatic subtype (per criteria)
Primary cutaneous B‑cell lymphoma: used as skin‑directed therapy for specified histologies (marginal zone or follicle center)